Notably, in the advanced metastatic stages of MM enclosed in this study, patients with PPARG-positive metastases versus PPARG-negative metastases show a significant survival benefit concerning progression-free survival (P = .044) not dependent on whether angiostatically scheduled metronomic chemotherapy (trofosfamide) was administered alone or in combination with pioglitazone (PPARG agonist) and rofecoxib (COX2 inhibitor) as additional biomodulatory therapy. The gene discussed is PTGS2; the disease is Miyoshi myopathy.